{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T21:13:42Z","timestamp":1779138822861,"version":"3.51.4"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T00:00:00Z","timestamp":1499299200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Drug Metab Pharmacokinet"],"published-print":{"date-parts":[[2018,2]]},"DOI":"10.1007\/s13318-017-0427-9","type":"journal-article","created":{"date-parts":[[2017,7,6]],"date-time":"2017-07-06T10:24:04Z","timestamp":1499336644000},"page":"69-80","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0144-0895","authenticated-orcid":false,"given":"Peter","family":"Stopfer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Giessmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathrin","family":"Hohl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashish","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell E.","family":"Taub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arvid","family":"Jungnik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dietmar","family":"Gansser","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Ebner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabian","family":"M\u00fcller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,7,6]]},"reference":[{"issue":"3","key":"427_CR1","doi-asserted-by":"publisher","first-page":"944","DOI":"10.1124\/pr.113.007518","volume":"65","author":"J K\u00f6nig","year":"2013","unstructured":"K\u00f6nig J, M\u00fcller F, Fromm MF. Transporters and drug-drug interactions: important determinants of drug disposition and effects. Pharmacol Rev. 2013;65(3):944\u201366. doi: 10.1124\/pr.113.007518 .","journal-title":"Pharmacol Rev"},{"issue":"3","key":"427_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1038\/nrd3028","volume":"9","author":"KM Giacomini","year":"2010","unstructured":"Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, et al. Membrane transporters in drug development. Nat Rev Drug Discov. 2010;9(3):215\u201336. doi: 10.1038\/nrd3028 .","journal-title":"Nat Rev Drug Discov"},{"issue":"6","key":"427_CR3","doi-asserted-by":"publisher","first-page":"798","DOI":"10.1038\/clpt.2010.354","volume":"89","author":"O Zolk","year":"2011","unstructured":"Zolk O, Fromm MF. Transporter-mediated drug uptake and efflux: important determinants of adverse drug reactions. Clin Pharmacol Ther. 2011;89(6):798\u2013805. doi: 10.1038\/clpt.2010.354 .","journal-title":"Clin Pharmacol Ther"},{"key":"427_CR4","unstructured":"EMA-CHMP. Guideline on the investigation of drug interactions: final (CPMP\/EWP\/560\/95\/Rev. 1 corr. 2). 2012 Jun. http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2012\/07\/WC500129606.pdf . Accessed 13 March 2017."},{"key":"427_CR5","unstructured":"US-FDA. Guidance for industry: drug interaction studies - study design, data analysis, implications for dosing, and labeling recommendations (draft guidance). 2012 Feb. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/ucm292362.pdf . Accessed 13 March 2017."},{"key":"427_CR6","unstructured":"PMDA. Pharmaceuticals & Medical Device Agency-Japan. Drug interaction guideline for drug development and labeling recommendations (draft for public comment) 2014. http:\/\/www.solvobiotech.com\/documents\/Japanese_DDI_guideline_(draft)_2014Jan.pdf . Accessed 13 March 2017."},{"issue":"4","key":"427_CR7","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1067\/mcp.2000.109519","volume":"68","author":"DS Streetman","year":"2000","unstructured":"Streetman DS, Bleakley JF, Kim JS, Nafziger AN, Leeder JS, Gaedigk A, et al. Combined phenotypic assessment of CYP1A2, CYP2C19, CYP2D6, CYP3A, N-acetyltransferase-2, and xanthine oxidase with the \u201cCooperstown cocktail\u201d. Clin Pharmacol Ther. 2000;68(4):375\u201383. doi: 10.1067\/mcp.2000.109519 .","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"427_CR8","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1111\/j.1365-2125.2009.03548.x","volume":"68","author":"S Turpault","year":"2009","unstructured":"Turpault S, Brian W, Van Horn R, Santoni A, Poitiers F, Donazzolo Y, et al. Pharmacokinetic assessment of a five-probe cocktail for CYPs 1A2, 2C9, 2C19, 2D6 and 3A. Br J Clin Pharmacol. 2009;68(6):928\u201335. doi: 10.1111\/j.1365-2125.2009.03548.x .","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"427_CR9","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1002\/cpt.406","volume":"100","author":"P Stopfer","year":"2016","unstructured":"Stopfer P, Giessmann T, Hohl K, Sharma A, Ishiguro N, Taub ME, et al. Pharmacokinetic evaluation of a drug transporter cocktail consisting of digoxin, furosemide, metformin, and rosuvastatin. Clin Pharmacol Ther. 2016;100(3):259\u201367. doi: 10.1002\/cpt.406 .","journal-title":"Clin Pharmacol Ther"},{"key":"427_CR10","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.525","author":"T Prueksaritanont","year":"2016","unstructured":"Prueksaritanont T, Tatosian DA, Chu X, Railkar R, Evers R, Chavez-Eng C, et al. Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A. Clin Pharmacol Ther. 2016;. doi: 10.1002\/cpt.525 .","journal-title":"Clin Pharmacol Ther"},{"issue":"9","key":"427_CR11","doi-asserted-by":"publisher","first-page":"3220","DOI":"10.1002\/jps.24489","volume":"104","author":"T Ebner","year":"2015","unstructured":"Ebner T, Ishiguro N, Taub ME. The use of transporter probe drug cocktails for the assessment of transporter-based drug\u2013drug interactions in a clinical setting\u2014proposal of a four component transporter cocktail. J Pharm Sci. 2015;104(9):3220\u20138. doi: 10.1002\/jps.24489 .","journal-title":"J Pharm Sci"},{"issue":"8","key":"427_CR12","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/j.clinthera.2014.06.004","volume":"36","author":"D Lee","year":"2014","unstructured":"Lee D, Roh H, Son H, Jang SB, Lee S, Nam SY, et al. Pharmacokinetic interaction between rosuvastatin and metformin in healthy Korean male volunteers: a randomized, open-label, 3-period, crossover, multiple-dose study. Clin Ther. 2014;36(8):1171\u201381. doi: 10.1016\/j.clinthera.2014.06.004 .","journal-title":"Clin Ther"},{"key":"427_CR13","unstructured":"US-FDA. CRESTOR (rosuvastatin calcium) tablets, Prescribing Information 2010. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/021366s016lbl.pdf . Accessed 20 June 2017."},{"key":"427_CR14","unstructured":"US-FDA. Guidance for industry: bioanalytical method validation. 2001 May. http:\/\/www.fda.gov\/downloads\/drugs\/guidancecomplianceregulatoryinformation\/guidances\/ucm070107.pdf . Accessed 13 March 2017."},{"key":"427_CR15","unstructured":"EMA-CHMP. Guideline on bioanalytical method validation EMEA\/CHMP\/EWP\/192217\/200921. 2011 Jul. http:\/\/www.ema.europa.eu\/ema\/pages\/includes\/document\/open_document.jsp?webContentId=WC500109686 . Accessed 13 March 2017."},{"key":"427_CR16","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1080\/00031305.1989.10475628","volume":"43","author":"LL Kupper","year":"1989","unstructured":"Kupper LL, Hafner KB. How appropriate are popular sample size formulas? Am Stat. 1989;43:101\u20135.","journal-title":"Am Stat"},{"issue":"3","key":"427_CR17","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1111\/bcp.12377","volume":"78","author":"T Prueksaritanont","year":"2014","unstructured":"Prueksaritanont T, Chu X, Evers R, Klopfer SO, Caro L, Kothare PA, et al. Pitavastatin is a more sensitive and selective organic anion-transporting polypeptide 1B clinical probe than rosuvastatin. Br J Clin Pharmacol. 2014;78(3):587\u201398. doi: 10.1111\/bcp.12377 .","journal-title":"Br J Clin Pharmacol"},{"issue":"10","key":"427_CR18","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1124\/dmd.108.021410","volume":"36","author":"S Kitamura","year":"2008","unstructured":"Kitamura S, Maeda K, Wang Y, Sugiyama Y. Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos Biol Fate Chem. 2008;36(10):2014\u201323. doi: 10.1124\/dmd.108.021410 .","journal-title":"Drug Metab Dispos Biol Fate Chem"},{"issue":"3","key":"427_CR19","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1124\/jpet.108.138073","volume":"326","author":"K Abe","year":"2008","unstructured":"Abe K, Bridges AS, Yue W, Brouwer KL. In vitro biliary clearance of angiotensin II receptor blockers and 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in sandwich-cultured rat hepatocytes: comparison with in vivo biliary clearance. J Pharmacol Exp Ther. 2008;326(3):983\u201390. doi: 10.1124\/jpet.108.138073 .","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"427_CR20","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1038\/clpt.2012.163","volume":"92","author":"R Elsby","year":"2012","unstructured":"Elsby R, Hilgendorf C, Fenner K. Understanding the critical disposition pathways of statins to assess drug\u2013drug interaction risk during drug development: it\u2019s not just about OATP1B1. Clin Pharmacol Ther. 2012;92(5):584\u201398. doi: 10.1038\/clpt.2012.163 .","journal-title":"Clin Pharmacol Ther"},{"key":"427_CR21","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ejps.2014.09.007","volume":"65","author":"S Bosgra","year":"2014","unstructured":"Bosgra S, van de Steeg E, Vlaming ML, Verhoeckx KC, Huisman MT, Verwei M, et al. Predicting carrier-mediated hepatic disposition of rosuvastatin in man by scaling from individual transfected cell-lines in vitro using absolute transporter protein quantification and PBPK modeling. Eur J Pharm Sci. 2014;65:156\u201366. doi: 10.1016\/j.ejps.2014.09.007 .","journal-title":"Eur J Pharm Sci"},{"issue":"6","key":"427_CR22","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1053\/j.gastro.2006.02.034","volume":"130","author":"RH Ho","year":"2006","unstructured":"Ho RH, Tirona RG, Leake BF, Glaeser H, Lee W, Lemke CJ, et al. Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology. 2006;130(6):1793\u2013806. doi: 10.1053\/j.gastro.2006.02.034 .","journal-title":"Gastroenterology"},{"issue":"10","key":"427_CR23","first-page":"775","volume":"69","author":"XY Lou","year":"2014","unstructured":"Lou XY, Zhang W, Wang G, Hu DL, Guo D, Tan ZR, et al. The effect of Na+\/taurocholate cotransporting polypeptide (NTCP) c.800C>T polymorphism on rosuvastatin pharmacokinetics in Chinese healthy males. Pharmazie. 2014;69(10):775\u20139.","journal-title":"Pharmazie"},{"issue":"6","key":"427_CR24","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1038\/clpt.2011.36","volume":"89","author":"H Kusuhara","year":"2011","unstructured":"Kusuhara H, Ito S, Kumagai Y, Jiang M, Shiroshita T, Moriyama Y, et al. Effects of a MATE protein inhibitor, pyrimethamine, on the renal elimination of metformin at oral microdose and at therapeutic dose in healthy subjects. Clin Pharmacol Ther. 2011;89(6):837\u201344. doi: 10.1038\/clpt.2011.36 .","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"427_CR25","doi-asserted-by":"publisher","first-page":"81","DOI":"10.2165\/11534750-000000000-00000","volume":"50","author":"GG Graham","year":"2011","unstructured":"Graham GG, Punt J, Arora M, Day RO, Doogue MP, Duong JK, et al. Clinical pharmacokinetics of metformin. Clin Pharmacokinet. 2011;50(2):81\u201398. doi: 10.2165\/11534750-000000000-00000 .","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"427_CR26","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00003088-199018050-00004","volume":"18","author":"LL Ponto","year":"1990","unstructured":"Ponto LL, Schoenwald RD. Furosemide (frusemide). A pharmacokinetic\/pharmacodynamic review (Part I). Clin Pharmacokinet. 1990;18(5):381\u2013408.","journal-title":"Clin Pharmacokinet"},{"key":"427_CR27","unstructured":"Glucophage (metformin hydrochloride tablets) 500\u00a0mg, 850\u00a0mg, and 1000\u00a0mg, Rx only (product information). Physician\u2019s Desk Ref. 2001;1005\u20139."}],"container-title":["European Journal of Drug Metabolism and Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s13318-017-0427-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s13318-017-0427-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,25]],"date-time":"2024-06-25T08:21:05Z","timestamp":1719303665000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s13318-017-0427-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,6]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,2]]}},"alternative-id":["427"],"URL":"https:\/\/doi.org\/10.1007\/s13318-017-0427-9","relation":{},"ISSN":["0378-7966","2107-0180"],"issn-type":[{"value":"0378-7966","type":"print"},{"value":"2107-0180","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,6]]}}}